Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment

Author(s): Emanuela Onesti , Vittorio Frasca , Marco Ceccanti , Giorgio Tartaglia , Maria Cristina Gori , Chiara Cambieri , Laura Libonati , Eleonora Palma , Maurizio Inghilleri* .

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 18 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The cannabinoid system may be involved in the humoral mechanisms at the neuromuscular junction. Ultramicronized-palmitoylethanolamide (μm-PEA) has recently been shown to reduce the desensitization of Acetylcholine (ACh)-evoked currents in denervated patients modifying the stability of ACh receptor (AChR) function.

Objective: To analyze the possible beneficial effects of μm-PEA in patients with myasthenia gravis (MG) on muscular fatigue and neurophysiological changes.

Method: The duration of this open pilot study, which included an intra-individual control, was three weeks. Each patient was assigned to a 1-week treatment period with μm-PEA 600 mg twice a day. A neurophysiological examination based on repetitive nerve stimulation (RNS) of the masseteric and the axillary nerves was performed, and the quantitative MG (QMG) score was calculated in 22 MG patients every week in a three-week follow-up period. AChR antibody titer was investigated to analyze a possible immunomodulatory effect of PEA in MG patients.

Results: PEA had a significant effect on the QMG score (p=0.03418) and on RNS of the masseteric nerve (p=0.01763), thus indicating that PEA reduces the level of disability and decremental muscle response. Antibody titers did not change significantly after treatment.

Conclusion: According to our observations, μm-PEA as an add-on therapy could improve muscular response to fatigue in MG. The possible modulation of AChR currents as a means of eliciting a direct effect from PEA on the conformation of ACh receptors should be investigated. The co-role of cytokines also warrants an analysis. Given the rapidity and reversibility of the response, we suppose that PEA acts directly on AChR, though further studies are needed to confirm this hypothesis.

Keywords: Myasthenia gravis, palmitoylethanolamide, PEA, ultramicronized-PEA, endocannabinoid system, neurophysiological.

[1]
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet 2015; 14: 1023-36.
[2]
Sanders DB, Wolfe GI, Benatar M. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87(4): 419-25.
[3]
Turkanis SA, Karler R. Changes in neurotransmitter release at a neuromuscular junction of the lobster caused by cannabinoids. Neuropharmacology 1988; 27(7): 737-42.
[4]
Sánchez-Pastor E, Trujillo X, Huerta M, Andrade F. Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction. J Pharmacol Exp Ther 2007; 321(2): 439-45.
[5]
Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 2016; 62: 107-28.
[6]
Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci 2016; 73(23): 4449-70.
[7]
Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 2017; 174(11): 1349-65.
[8]
Hansen HS. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 2010; 224(1): 48-55.
[9]
Freitag CM, Miller RJ. Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines? Front Cell Neurosci 2014; 8: 238.
[10]
Skaper SD, Facci L, Fusco M. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 2014; 22(2): 79-94.
[11]
Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician 2016; 19(2): 11-24.
[12]
Skaper SD, Facci L, Barbierato M, et al. N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol 2015; 52: 1034-42.
[13]
Palma E, Reyes-Ruiz JM, Lopergolo D, et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Natl Acad Sci USA 2016; 113(11): 3060-5.
[14]
Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinois: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521-8.
[15]
Di Marzo V, Deutsch DG. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 1998; 5: 386-404.
[16]
Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 2005; 166(1-2): 3-18.
[17]
Salzet M, Breton C, Bisogno T, Di Marzo V. Comparative biology of the endocannabinoid system. Possible role in the immune response. Eur J Biochem 2000; 267: 4917-27.
[18]
Kharraz Y, Guerra J, Mann CJ, Serrano AL, Muñoz-Cánoves P. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm 2013; 2013: 491-7.
[19]
Jaretzki A, Barohn RJ, Ernstoff RM. Myasthenia gravis: recommendations for clinical research standards. Task Force of the medical scientific advisory board of the myasthenia gravis foundation of America. Ann Thorac Surg 2000; 70(1): 327-34.
[20]
Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005; 64(11): 1968-70.
[21]
Pavesi G, Cattaneo L, Tinchelli S, Mancia D. Masseteric repetitive nerve stimulation in the diagnosis of myasthenia gravis. Clin Neurophysiol 2011; 112(6): 1064-9.
[22]
Kimura J. Electrodiagnosis in diseases of the nerve and muscle: principles and practice 3rd ed Philadelphia PA: Davis. 1989.
[23]
Orefice NS, Alhouayek M, Carotenuto A. Oral Palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of Interferon-β1a and circulating proinflammatory cytokines in relapsing-remitting Multiple Sclerosis. Neurotherapeutics 2016; 13(2): 428-38.
[24]
Caltagirone C, Cisari C, Schievano C, et al. Stroke study group Stroke study group. Co-ultramicronized Palmitoylethanolamide/Luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res 2016; 7(1): 54-69.
[25]
Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets 2017; 16(6): 705-13.
[26]
Esposito E, Paterniti I, Mazzon E, et al. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun 2011; 25(6): 1099-112.
[27]
D’Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A. Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 2012; 37(7): 1784-92.
[28]
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008; 139(3): 541-50.
[29]
De Filippis D, Luongo L, Cipriano M, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 2011; 7: 3.
[30]
Di Cesare Mannelli L, D’Agostino G, Pacini A, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013; 328797.
[31]
Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12(1): 34-44.
[32]
Impellizzeri D, Bruschetta G, Cordaro M, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 2014; 11: 136.
[33]
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995; 92(8): 3376-80.
[34]
Paterniti I, Cordaro M, Campolo M, et al. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer’s disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets 2014; 13(9): 1530-41.
[35]
Petrosino S, Schiano Moriello A, Cerrato S. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol 2016; 173(7): 1154-62.
[36]
Vacondio F, Bassi M, Silva C. Amino acid derivatives as Palmitoylethanolamide prodrugs: synthesis, in vitro metabolism and in vivo plasma profile in rats. PLoS One 2015; 10(6): e0128699.
[37]
Clemente S. Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report. CNS Neurol Disord Drug Targets 2012; 11(7): 933-6.
[38]
Colón-Sáez JO, Yakel JL. The α7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane. J Physiol 2011; 589(Pt 13): 3163-74.
[39]
Trujillo X, Sánchez-Pastor E, Andrade F, Huerta M. Presence and colocalization of type-1 cannabinoid receptors with Acetylcholine receptors in the motor end-plate of twitch skeletal muscle fibers in the frog. J Membr Biol 2014; 247(11): 1199-205.
[40]
Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010; 58(9): 1017-30.
[41]
Silveira PE, Silveira NA, Morini Vde C, Kushmerick C, Naves LA. Opposing effect of cannabinoids and vanilloids on evoked quantal release at the frog neuromuscular junction. Neurosci Lett 2010; 473(2): 97-101.
[42]
Newman Z, Malik P, Wu TY, Ochoa C, Watsa N, Lindgren C. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci 2007; 25(6): 1619-30.
[43]
Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol 2014; 176: 232-7.
[44]
Roche JC, Capablo JL, Larrad L, et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011; 44(2): 278-80.
[45]
Yilmaz V, Oflazer P, Aysal F, et al. B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis. Autoimmunit 2015; 48: 201-7.
[46]
Oh S, Eslami N, Nishihira T, Sarala PK. Electrophysiological and clinical correlation in myasthenia gravis. Ann Neurol 1982; 12: 348-54.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 3
Year: 2019
Page: [232 - 238]
Pages: 7
DOI: 10.2174/1871527318666190131121827
Price: $58

Article Metrics

PDF: 29
HTML: 1